Business Operations
We Serve Customers Across the Pharma Value Chain — from custom CDMO synthesis to high-capacity commercial API manufacturing.
We Serve Customers Across the Pharma Value Chain
Our vision & execution priorities are focused on the needs of our global customers. We champion customer success through continual scientific innovation. Working together with our academic/industry partners, we continually investigate and embrace new technologies to enhance customer value.
We aim to be a market leader in all the 15 to 20 APIs that we currently produce. As a result, most of our products are in continuous manufacturing, with a maximum lead time of 8 to 10 weeks, which, in turn, helps our clients maintain their inventory levels more effectively.
We ensure clients success through our diverse teams of experts with over two decades of industry experience, spanning R&D, regulatory affairs, operations, supply chain, and IT.
Dedicated Client Segment Teams
Originators & Innovators
For originators and innovators, a cross-functional team led by the R&D head handles enquiries and technical discussions.
Specialty Chemicals
In specialty chemicals, a dedicated team manages commercial and technical requirements, ensuring seamless project execution from R&D to commercial manufacturing.
Generic Clients
For generic clients, our robust sales and business development team coordinates with production and supply chain teams to meet specific requirements and timelines.
We Retain Their Trust
Chieron is a strategic Partner for CDMO/CMO Opportunities, API/Intermediates for USA/Japan & European Customers. Today, the company has clients across India, Europe, Brazil, Korea, Japan, China, the US, and the Middle East.
With a strong foundation built on backward integration, green chemistry, and regulatory compliance, we aspire to be recognized for our quality and delivery commitments and, eventually, achieve a top-three global position for all our products.
Chieron emphasizes transparency and proactive communication with our clients to mitigate challenges like price fluctuations. Explaining the impact of price fluctuations and maintaining consistent quality and supply has helped us retain their trust and loyalty.
CDMO - Integrated from concept to commercialisation.
Capability - Proven in 20+ API & still developing. Chieron is on a growth trajectory, with plans to introduce four to seven new API molecules annually, along with new specialty chemicals, while also exploring opportunities in new chemical entities (NCE) with originators.
Commercial Product Portfolio
| Commercial Product Name |
|---|
| Allyl isopropyl acetyl urea (AIPAU) |
| Benfotiamine |
| Dapagliflozin Propanediol |
| Lacosamide |
| Levetiracetam |
| Linagliptin |
| Loxoprofen Acid |
| Loxoprofen Sodium |
| Olmesartan Medoxomil |
| Oseltamivir |
| Risperidone |
| Rivaroxaban |
| Sitagliptin Phosphate (Enzymatic) |
| Tetracaine Base |
| Tetracaine HCL |
| Vildagliptin |
| Warfarin Sodium Amorphous |
| Warfarin Sodium Clathrate |
API Pipeline — Under Development
Adenosine Triphosphate (ATP)Q3 Fy26 | Azilsartan medoxomil PotassiumQ4 Fy26 | Bempedoic AcidQ4 Fy26 |
Biphenyl Dimethyl Dicarboxylate (BDD)Q4 Fy26 | Eflornithine HClQ1 Fy27 | Eprazinone dihydrochlorideQ3 Fy26 |
EzetimibeQ1 Fy27 | FexofenadineQ4 Fy26 | FlupirtineQ4 Fy26 |
IpragliflozinQ1 Fy27 | LoratadineQ4 Fy26 | LusiogliflozinQ1 Fy27 |
Mirogabalin BesylateQ1 Fy27 | OpicaponeQ1 Fy27 | PelubiprofenQ4 Fy26 |
Prenoxdiazine HClQ1 Fy27 | RebamipideQ4 Fy26 | TofogliflozinQ1 Fy27 |
TrazodoneQ3 Fy26 |
BilastineQ4 Fy26 | FamotidineQ3 Fy26 | LercanidipineQ4 Fy26 |
API Pipeline — Under Evaluation
| Product Name | ||
|---|---|---|
| Acoramidis | Anagliptin | Dorzagliatin |
| Elafibranor | Fenfluramine | Fimasartan |
| Finerenone | Fluvoxamine Maleate | Fosravuconazole |
| Ipragliflozin | Isavuconazole | Letermovir |
| Lumateperone | Mavacamten | Nafamostat |
| Retagliptin | Risdiplam | Roxadustat |
| Sotagliflozin | Tolvaptan | Vilanterol |